文献速递内脏/肾动脉与血管畸形静脉血栓栓塞

静脉性肠系膜缺血:干预负担高且重症患者死亡率升高

Venous mesenteric ischemia carries high procedural burden and elevated mortality in patients with severe presentation.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-03-17

本研究回顾性分析了1993至2016年间103例急性和亚急性静脉性肠系膜缺血(VMI)患者,旨在描绘其自然病史并识别干预与不良结局的驱动因素。结果显示30天死亡率较低(6.8%),但超过三分之一患者需要抗凝以外的干预,合并症、既往肠系膜血管或肠道手术、腹部压痛及乳酸升高提示预后更差,早期干预与改善结局相关。

要点

  • 超过三分之一VMI患者需要抗凝以外的干预,30天死亡率为6.8%。
  • 既往肠系膜静脉操作、腹部压痛和乳酸>1.5 mmol/L与需外科干预风险增加相关。
  • 需要干预者30天死亡率升至11.4%,住院第0-1天干预者死亡率低于第2天及以后(8.7% vs 16.7%)。

核心结论

  • VMI的30天死亡率较低,但超过三分之一患者需要抗凝以外的干预。
  • 合并症、既往肠系膜血管或肠道手术、腹部压痛或相关实验室异常提示结局更差。
  • 早期干预与改善结局相关。

研究设计与样本

  • 回顾性队列研究,纳入1993至2016年本院就诊的103例急性和亚急性VMI患者。
  • 通过影像学确定血栓位置,病历回顾收集临床因素和结局。
  • 采用单变量分析及生存分析(log-rank检验)评估 demographic、合并症和表现特征与干预、再入院及30天死亡率的关系。

主要发现

  • 血栓位置包括肠系膜上静脉(SMV)31.1%、SMV和门静脉35.9%、SMV+门静脉+脾静脉15.5%、其他门肠系膜静脉组合17.4%,位置与结局无相关性。
  • 患者男性占60.6%,当前吸烟22.3%,Charlson合并症评分中位数4(IQR 2-7),平均年龄61.3岁。
  • 52.4%有已知高凝状态,22.3%有既往肠切除,8.7%有既往肠系膜静脉干预(包括TIPS)。
  • 35例患者住院期间共接受83次操作,23例接受外科干预。
  • 既往肠系膜静脉操作、腹部压痛和乳酸>1.5 mmol/L与需外科干预风险增加相关(P < .05);症状<2周与外科干预减少相关(P < .05)。

临床怎么用

  • 对VMI患者应评估合并症、既往肠系膜血管或肠道手术史、腹部压痛及乳酸水平以识别高危人群。
  • 腹部压痛或乳酸>1.5 mmol/L提示可能需要外科干预,应尽早决策。
  • 需干预者应尽量在住院第0-1天实施以改善30天死亡率。

局限性

  • 单中心回顾性研究,样本量103例,结论外推需谨慎。
  • 未报告多变量分析校正混杂因素(除生存分析外)。
  • 白细胞增多>10K/μL与外科干预的关联无统计学显著性(P = .10)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Venous mesenteric ischemia (VMI) presents with variable severity resulting in a spectrum of outcomes. This study sought to characterize the natural history of VMI and identify drivers of intervention and adverse outcomes. METHODS: All patients who presented to our institution with acute and subacute VMI between 1993 and 2016 were identified. Images were reviewed to determine thrombosis location and charts were reviewed to identify clinical factors and outcomes. Univariate analysis was performed for demographics, comorbidities, and presenting characteristics, with primary outcomes of intervention, readmission, and 30-day mortality. A survival analysis was performed with log-rank difference testing for demographics, comorbidities, and presenting characteristics. RESULTS: We identified 103 patients with acute and subacute VMI. The locations of the thrombosis included the superior mesenteric vein (SMV) (31.1%); SMV and portal vein (35.9%); SMV, portal, and splenic veins (15.5%); and other combinations of portomesenteric veins (17.4%), without correlation between the location and outcomes. Most patients were male (60.6%), 22.3% were actively smoking, and the median Charlson comorbidity score was 4 (interquartile range, 2-7). The mean patient age was 61.3 years. More than one-half had a known hypercoagulability (52.4%), 22.3% had prior bowel resection, and 8.7% had prior mesenteric venous intervention, including transjugular intrahepatic portosystemic shunt procedures. Thirty-five patients underwent 83 procedures during their hospitalization, and 23 patients underwent surgical intervention specifically. Prior mesenteric venous procedure, abdominal tenderness, and lactatemia of more than 1.5 mmol/L were associated with an increased need for surgical intervention (P < .05). Patients with leukocytosis of greater than 10K/μL had increased surgical intervention (P = .10), although without statistical significance. However, symptoms for less than 2 weeks (P < .05) were associated with decreased surgical intervention. The 30-day mortality was low in this cohort (6.8%), but was increased in patients requiring intervention (11.4%). For those undergoing procedures, a shorter time to intervention was associated with an improved 30-day mortality (8.7% for procedures on hospital days 0-1 vs 16.7% for hospital day 2 or later; P = .01). Abdominal tenderness and lactatemia were associated with increased 30-day mortality (6.8% vs 3.6% [P < .01] and 16.0% vs 3.8% [P = .03], respectively). A Kaplan-Meier survival analysis revealed a median survival of 7.1 years, with a 1-year survival rate of 74.9%, a 3-year survival rate of 67.1%, and a 5-year survival rate of 57.9%. Negative predictors of survival included a higher Charlson comorbidity index (hazard ratio, 3.7; P < .01) and malignancy (hazard ratio, 3.1; P < .01). CONCLUSIONS: The 30-day mortality of VMT is low, but more than one-third of patients required an intervention beyond anticoagulation. Comorbidity, a prior mesenteric vessel or intestinal operation, and presentation with tenderness or relevant laboratory abnormalities portend worse outcomes. Early intervention is associated with improved outcomes.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Feldman ZM, Wang LJ, Chou EL, et al. Venous mesenteric ischemia carries high procedural burden and elevated mortality in patients with severe presentation. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33741519. doi:10.1016/j.jvsv.2021.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。